Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer

NCT05263882 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

58

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative Breast Cancer

Interventions

DRUG: Gemcitabine combined with eribulin

Sponsor

Fifth Affiliated Hospital, Sun Yat-Sen University